Related Experiment Video
Updated: Jul 17, 2026
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Discovery of a vaccine antigen that protects mice from Chlamydia pneumoniae infection
Callum Thorpe1, Lorna Edwards, Robert Snelgrove
1Kennedy Institute of Rheumatology, Imperial College London, Charing Cross Hospital Campus, 1 Aspenlea Rd., Hammersmith, London W8 8LH, UK.
Abstract:
Chlamydiae are atypical intracellular bacteria that infect via mucosal surfaces causing, for example, trachoma, pneumonia, cervicitis, urethritis and infertility. Existing antibiotics are only partially effective and no vaccines are available. Using surface expressed or secreted proteins previously identified by genomics and proteomics we tested five as vaccines against intranasal challenge with Chlamydia pneumoniae. One antigen, LcrE, induced CD4+ and CD8+ T cell activation, type 1 cytokine secretion and neutralising antibodies and was completely effective in eliminating infection. Such antigens are highly conserved and essential to all Chlamydial species. The discovery of an effective vaccine for Chlamydiae pneumoniae has potential wide benefits for human health.
Insights
A novel vaccine targeting Chlamydia pneumoniae, an atypical bacterium, has shown complete effectiveness in eliminating infection. This breakthrough offers significant potential for improving human health by addressing widespread chlamydial diseases.
Area of Science:
- Microbiology
- Immunology
- Vaccine Development
Background:
- Chlamydiae are atypical intracellular bacteria causing significant human diseases like trachoma and pneumonia.
- Current antibiotic treatments for chlamydial infections are only partially effective, and no vaccines are currently available.
- Chlamydial infections pose a global health challenge due to their prevalence and associated morbidities.
Purpose of the Study:
- To evaluate the efficacy of novel vaccine candidates against Chlamydia pneumoniae infection.
- To identify specific antigens capable of inducing protective immune responses against chlamydial pathogens.
- To explore the potential of surface-expressed or secreted proteins as vaccine targets.
Main Methods:
- Utilized genomics and proteomics to identify potential vaccine antigens.
- Tested five candidate antigens as vaccines against intranasal challenge with Chlamydia pneumoniae.
- Assessed immune responses including T cell activation, cytokine secretion, and antibody production.
Main Results:
- One antigen, LcrE, successfully induced CD4+ and CD8+ T cell activation.
- LcrE vaccination led to type 1 cytokine secretion and the generation of neutralizing antibodies.
- Vaccination with LcrE resulted in the complete elimination of Chlamydia pneumoniae infection in the challenge model.
- The identified antigen LcrE is highly conserved and essential across Chlamydial species.
Conclusions:
- LcrE is a highly effective vaccine candidate against Chlamydia pneumoniae.
- The development of an LcrE-based vaccine holds significant promise for preventing and treating chlamydial infections.
- This research opens avenues for broad-spectrum vaccines against various chlamydial species, benefiting global public health.
